Application of Indocyanine Green Tracer in D2 Lymphadenectomy of Locally Advanced Gastric Cancer
Launched by HOSPITAL OF NAVARRA · Mar 18, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new technique to help doctors remove lymph nodes during surgery for patients with locally advanced gastric cancer. The study will use a special dye called indocyanine green (ICG) that helps highlight lymph nodes, making it easier for surgeons to identify and remove them. The main goal is to see if this technique can increase the number of lymph nodes removed during surgery, which is important for accurately staging the cancer and improving patient outcomes.
To be eligible for this trial, participants should be between the ages of 65 and 74 and have certain types of gastric cancer (specifically, stages T2 to T4a, with lymph node involvement but no distant spread). Patients will need to be in reasonably good health and able to undergo laparoscopic surgery, which is a minimally invasive approach. Those who have had previous abdominal surgeries, certain medical conditions, or allergies to iodine will not be eligible. Participants can expect to be part of a multicenter study, meaning it will take place in various locations, and they will be monitored closely to assess how well the new technique works over time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • T2-T4a, N+, M0 on preoperative study
- • PS 0-1
- • ASA I-III
- • Laparoscopic surgery
- Exclusion Criteria:
- • - Previous gastric abdominal surgery
- • DSE
- • Cognitive impairment
- • Allergic to iodine
- • Synchronous neoplasm
- • Stroke in the last 6 months
- • Angina or AMI in the last 6 months
- • Plastic lymphitis
- • Open surgery
About Hospital Of Navarra
The Hospital of Navarra is a leading healthcare institution in Spain, renowned for its commitment to advancing medical research and patient care. As a prominent clinical trial sponsor, the hospital actively engages in innovative research initiatives aimed at improving treatment outcomes and enhancing the understanding of various medical conditions. With a multidisciplinary team of experienced healthcare professionals and researchers, the Hospital of Navarra fosters a collaborative environment that prioritizes ethical standards and rigorous scientific methodology. Its participation in clinical trials not only contributes to the global body of medical knowledge but also ensures that patients have access to cutting-edge therapies and interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pamplona, Navarra, Spain
Patients applied
Trial Officials
Maria Concepcion Yarnoz, MD, PhD
Study Chair
Hospital of Navarra
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported